Business context and reporting period
Important entity distinction: The supplied 10-Q is filed by Alpha Healthcare Acquisition Corp. (AHAC), a blank-check company, not by Humacyte, Inc. It reports the three months ended March 31, 2021; it does not provide Humacyte’s operating results or financial statements.
AHAC reported that it entered into a business combination agreement with Humacyte on February 17, 2021. The proposed transaction would merge a subsidiary into Humacyte, with Humacyte surviving as AHAC’s wholly owned subsidiary; AHAC anticipated changing its name to Humacyte, Inc. The filing describes AHAC as pre-combination and without operating revenue.
Financial results, liquidity and capital
- Revenue: None. AHAC had not commenced operations and expected no operating revenue before a business combination.
- Net loss: $9.44 million for Q1 2021, including $493,818 of formation and operating costs and an $8.96 million loss from the change in fair value of warrant liabilities. The warrant remeasurement is noncash.
- Cash flow: $493,738 used in operating activities and $87,964 used in financing activities; cash declined $581,702 to $513,059 outside the trust account.
- Assets and liquidity: Total assets were $100.67 million, including $100.03 million held in trust and generally unavailable for operating expenses before a business combination. Management said the $513,059 of outside cash was expected to fund operations for at least 12 months from issuance, assuming no business combination during that period.
- Liabilities and obligations: Total liabilities were $17.26 million, including $14.99 million of warrant liabilities, $2.13 million of deferred underwriting discount, and $135,647 of current liabilities. The $7,172 related-party promissory note balance was current. The deferred underwriting fee is payable upon completion of a business combination.
- Margins and debt: Operating or profit margins are not meaningful for this pre-operating SPAC. The filing reports no long-term debt; potential working-capital loans from affiliates were not committed.
Changes and unusual items
Compared with December 31, 2020, cash outside the trust fell from $1.09 million to $513,059, while trust assets rose from $100.02 million to $100.03 million. Warrant liabilities increased from $6.04 million to $14.99 million, driving the large reported quarterly loss. Class A shares subject to possible redemption decreased from 8,801,384 to 7,841,024.
AHAC disclosed that it restated its December 31, 2020 financial statements after revising its accounting for warrants. Management concluded disclosure controls were ineffective due to a material weakness in evaluating complex accounting issues. The filing says the restatement did not change previously reported cash or total assets; planned remediation included increased communication with personnel and external professionals.
Outlook, risks and contingencies
AHAC intended to seek a healthcare business combination, but the filing does not provide transaction closing guidance or Humacyte forecasts. The company warned that available operating cash could prove insufficient if diligence and transaction costs exceed estimates; sponsor, officer and director funding was not assured. COVID-19 could affect the search and transaction process, though the specific impact was not determinable. Public shareholders could redeem shares in connection with a business combination; if AHAC failed to complete one within 24 months of its September 2020 IPO, it was required to redeem public shares, subject to the filing’s terms.
Investor verification priorities
- Confirm the issuer: this is AHAC’s 10-Q, not a Humacyte 10-Q, and obtain Humacyte’s own financial filings for its operating performance.
- Review the merger agreement, transaction financing, required approvals, redemption levels, and subsequent transaction developments; this filing alone does not establish closing or final economics.
- Assess the warrant-liability valuation and accounting restatement, including the disclosed material weakness and remediation progress.
- Verify unrestricted cash needs and any related-party or other financing actually available; trust funds are restricted before a qualifying transaction.
- Note the filing’s cover page indicates AHAC marked “No” for having filed all required reports during the preceding 12 months; verify filing compliance and any related disclosures.